April 6, 2011

Biogen Idec submitted an investigational new drug (IND) application

Biogen Idec submitted an investigational new drug (IND) application to the FDA to evaluate its anti-beta-amyloid antibody BART (BIIB037) as a potential new treatment for Alzheimer's disease. BIIB037 binds to parenchymal amyloid and clears parenchymal plaques in transgenic mice without causing microbleeds.

Read more